Decline in revenue from the drug discovery business and increase in revenue from Fine Tech
First written in FY2022-Q3. 11 of 14 entries say "Reframed", first in FY2023-Q1. Latest entry: 2026-08-07.
No other company in this theme has enough history to compare yet.
- FY2026-H1ReframedAnnual report
「Overseas revenue from Livaro (an antihyperlipidemic drug) API increased. Finetech (a contract business focused on solving customer challenges and a joint development business) posted lower revenue.」
In the Healthcare segment, overseas revenue from Livaro increased, while Finetech posted lower revenue. Conditions by business changed from lower domestic and overseas Livaro revenue and higher Finetech revenue in the first half of the previous fiscal year. - FY2025-H1ReframedAnnual report
「Revenue from Livaro (an antihyperlipidemic drug) API declined both domestically and overseas. Finetech (a contract business focused on solving customer challenges and a joint development business) posted higher revenue.」
Business conditions by product changed from Livaro revenue being broadly in line with the previous year and lower Finetech revenue in the third quarter of the previous fiscal year to lower Livaro revenue both domestically and overseas and higher Finetech revenue. - FY2024-Q3ReframedAnnual report
「Revenue from Livaro (an antihyperlipidemic drug) API was broadly in line with the previous year. Finetech (a contract business focused on solving customer challenges) posted lower revenue.」
Livaro API revenue improved from a decline in the previous quarter to being broadly in line with the previous year, while Finetech continued to post lower revenue. - FY2024-Q2ReframedAnnual report
「Revenue from the domestic and overseas sales of Livaro (an antihyperlipidemic drug) API declined. Finetech posted higher revenue.」
In the Healthcare segment, revenue from Livaro API declined both domestically and overseas, while Finetech posted higher revenue. The explanation has become more specific about conditions by product and business, compared with the previous quarter's description that both the Healthcare business and Finetech were performing steadily. - FY2024-Q1ReframedAnnual report
「Revenue from the domestic and overseas sales of Livaro (an antihyperlipidemic drug) API declined. Finetech posted higher revenue.」
Revenue from Livaro API declined both domestically and overseas, while Finetech posted higher revenue. The trend of higher full-year Finetech revenue from the previous fiscal year has continued, but performance has diverged by product within the Healthcare segment. - FY2023ReframedAnnual report
「Sales of Livaro, the active pharmaceutical ingredient for a treatment for hypercholesterolaemia, were at the same level as the previous year. Finetech generated higher revenue as sales of generic active pharmaceutical ingredients progressed smoothly.」
The explanation has changed from a decline in revenue in the most recent quarter due to delayed Finetech shipments to an expectation of higher full-year revenue on solid generic API sales. - FY2023-Q3RestatedAnnual report
「Sales of Livaro, the active pharmaceutical ingredient for a treatment for hypercholesterolaemia, to overseas markets decreased. Finetech, a contract business focused on problem-solving, generated lower revenue due to factors including shifts in shipping schedules.」
The Healthcare segment continued to report lower overseas shipments of Livaro and lower revenue from Finetech compared with the previous quarter. - FY2023-Q2ReframedAnnual report
「Sales of Finetech, a contract business focused on problem-solving, decreased in the Healthcare segment.」
The explanation has changed from both the Healthcare business and Finetech performing steadily in the previous quarter to Finetech generating lower revenue in the current quarter due to factors including shifts in shipping schedules. - FY2023-Q1ReframedAnnual report
「Both the Healthcare business and Finetech, a contract business focused on pharmaceutical technology development, performed steadily in the Healthcare segment.」
The explanation has changed from the previous fiscal year’s indication of lower revenue in the drug discovery business and higher revenue from Finetech to both the Healthcare business and Finetech performing steadily. - FY2022-Q3First statedAnnual report
「In the Pharmaceuticals segment, the drug discovery business generated lower revenue, while Finetech, a contract business focused on pharmaceutical technology development, generated higher revenue.」
Within the Pharmaceuticals segment, the drug discovery business generated lower revenue, while Finetech generated higher revenue.